Table 2 The effect of methotrexate or azathioprine on the formation of antibodies against adalimumab or infliximab
Study | Disease | TmAbs | IS used | % AAAs or ATIs | IS + % AAAs or ATIs | IS - % AAAs or ATIs | Pvalue | Assay |
|---|---|---|---|---|---|---|---|---|
Maini et al. [4] | RA | IFX | MTX | 17.4% | 0%-15% | 7%-53% | NA | LoBuglio et al. [30] |
Vermeire et al. [13] | Crohn | IFX | AZA | 55% | 46% | 73% | P < 0.001 | Prometheus Laboratories |
| Â | Â | Â | MTX | Â | Â | Â | Â | (San Diego, CA, USA) |
Baert et al. [10] | Crohn | IFX | MTX | 61% | 43% | 75% | P < 0.01 | Prometheus Laboratories |
ACCENT I [11] | Crohn | IFX | MTX | 14% | 10% | 18% | NA | NA |
ACCENT II [12] | Crohn | IFX | MTX | 32% | 11% | 24% | NA | NA |
Colombel et al. [25] | Crohn | IFX | AZA | NA | 0.9% | 14.6% | NA | NA |
Bartelds et al. [7] | RA | ADA | MTX | 17% | 12% | 38% | NA | Sanquin (Amsterdam, The Netherlands) |
Lovell et al. [18] | JIA | ADA | MTX | 16% | 6% | 26% | NA | NA |
West et al. [16] | Crohn | ADA | MTX | 17% | 7.7% | 20% | NA | Sanquin |
CLASSIC II [15] | Crohn | ADA | MTX | 2.6% | 0% | 3.8% | NA | NA |